Kite's Fosun-Partnered CAR-T Immunotherapy Posts Strong Phase III Data

Kite Pharma of Santa Monica, California reported very positive topline results from a US Phase III trial of its lead CAR-T immunotherapy in patients with chemorefractory B-cell non-Hodgkin lymphoma (NHL). Two months ago, Fosun Pharma and Kite announced a $95 million JV to develop the candidate in China. In the Phase III trial, a single infusion of Kite's axicabtagene ciloleucel produced a complete response in 36% of the patients at the 6-month checkpoint. That compares to an 8% complete response from usual treatments. Kite will complete its NDA filing of the CAR-T therapy in the US during Q1 and in Europe later this year. More details.... Stock Symbols: (NSDQ: KITE) (SHA:600196; HK:02196) Share this with colleagues: // //